A study by scintigraphy to evaluate the effect of exenatide on gastric emptying in subjects with type 2 diabetes

Trial Profile

A study by scintigraphy to evaluate the effect of exenatide on gastric emptying in subjects with type 2 diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Amylin Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2013 Actual end date Jun 2005 added as reported by ClinicalTrials.gov.
    • 28 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top